Moleac’s product NeuroAiD named Asia’s new product innovation of the year for neurological disorders
NeuroAiD™ stroke treatment, marketed by Bolar Pharmaceuticals in Nigeria, has been named New Product Innovation of the Yearby Frost & Sullivan. This award recognizes healthcare products that are bringing innovative solutions for neurological disorders by pushing the boundaries of the usual practices. This award also acknowledges Moleac for its effort and continuous investment in NeuroAiDTM’s Research and Development. Mr. David Picard, CEO of Moleac, received the 2016 Frost & Sullivan Asia Pacific New Product Innovation Award at the awards ceremony held at Conrad Singapore. The ceremony was attended by leaders from the healthcare sector.
Frost & Sullivan followed a rigorous measurement-based methodology to select NeuroAiD™ as the recipient. Its independent panel of judges included senior members across various offices at Frost & Sullivan. The judging panel looked at market performance indicators, including revenue growth, market share, availabilities, geographical expansion and marketing strategies.
Dr. M. Shaillender, Industry Analyst, Healthcare Practice – Asia Pacific at Frost & Sullivan, said, “Stroke rehabilitation is an underserved segment in the pharmaceutical industry. Moleac aims to address the existing gaps in stroke therapy with an unconventional approach similar to ’reverse innovation.’ NeuroAiD™ is a product originating from Traditional Chinese Medicine that has demonstrated excellent attributes in post-stroke recovery, however, without any scientific and clinical evidence. Moleac’s team was instrumental in identifying and decoding the underlying neuromodulatory properties to translate it into a therapeutic drug supported by clinical evidence for neurological disorders.”
He further adds, “As one of the first therapies of its kind, NeuroAiD™ is today accepted as an innovative treatment for post-stroke recovery. It is approved and marketed in over 35 countries as a supplement for stroke rehabilitation. Executing well in its vision, Moleac is on a trajectory to expand the horizons of NeuroAiD™into a mainstream therapeutic drug for neurological disorders.”
David Picard, CEO of Moleac, said, ”I am delighted to receive this award from Frost & Sullivan while we are celebrating the 10 years’ anniversary of NeuroAiD™. Having launched NeuroAiD™ in 2006, we have been focusing our efforts on making NeuroAiDTM available to stroke sufferers around the world. NeuroAiD™ is the first medicine to support stroke recovery, and this is a huge unserved need for millions of suffers. In 2016, over 20,000 patients benefited from NeuroAiD™ worldwide and we aim at making NeuroAiD™ available to more patients in the coming years.”
He continued to add, “I would like to thank all those who have contributed to NeuroAiDTM’s development over the past 10 years. This includes our academic partners, who have shown interest in our approach enabling its clinical development, our investors who have trusted us, and of course my colleagues who have made this venture a success. Without their support, NeuroAiD™ would not be where it is today. We keep investing in Research with several on-going clinical studies to provide first-class evidences of NeuroAiDTM’s benefits in other unserved neurological disorders.
Bolade Soremekun, CEO Bolar Pharmaceuticals Nigeria said “Bolar is delighted unserved neurological disorders.” to partner with Moleac in bringing NeuroAiD™ to Nigeria. NeuroAiD™ is a perfect fit for Bolar as we are not a generic company, but a company focused on searching for unique, research based, effective solutions for disease areas where current treatments are either inadequate, unavailable, or unaffordable. Stroke is one of such. NeuroAiD™ brings hope to millions of stroke sufferers in Nigeria and we are glad to partner with Neurologists, GPs and private and public sectors to make this life saving product available nationwide. Bolar also offers unique products in the areas of hepatitis, sickle cell, and immunity.”
NeuroAiD™ is a natural medicine originating from Traditional Chinese Medicine.
In addition to its excellent safety profile, clinical trials have shown that patients taking NeuroAiD™ for 3 months have higher chances to reach functional recovery, with prolonged benefits over the long-term as published in Cerebrovascular Diseases (April 2015). About 3,000 subjects have been included in clinical trials and Moleac is currently supporting additional international clinical trials to demonstrate the potential of NeuroAiD™ in other neurological disorders.
About Moleac: Moleac is a Singapore-based biopharmaceutical company that dedicates itselfto finding and developing new medicines for the unmet needs of patients worldwide.
About Bolar: Bolar is a Nigerian Pharmaceutical company which has partnered with Moleac to market and distribute NeuroAiDTM in Nigeria. Bolar is focused on identifying researched based natural, herbal and chemical remedies that address unmet medical needs and are useful in therapeutic areas where current treatments are either unavailable, inadequate, or unaffordable.
About NeuroAiD™: NeuroAiD™ is a post-stroke recovery treatment to help stroke survivors achieve a faster and better recovery. It currently reaches out to patients in over 35 countries.
Contact details: Bolar Pharmaceutical Ltd,
5 Talabi street, Off Adeniyi Jones avenue,
Ikeja, Lagos. 0700bolarpharm, 08133289839,
07054817887, info@ bolarpharm .com, www.bolarpharm.com.
BOLADE A SOREMEKUN,